CClinicalTrials.gg
Status unknownNCT04430244Updated Jul 7, 2020

Deep Anterior Lamellar Keratoplasty Using Dehydrated Versus Standard Organ Culture Stored Donor Corneas

An interventional study of Deep anterior lamellar keratoplasty and Deep anterior lamellar keratoplasty in Keratoconus, sponsored by Istituto Internazionale di Ricerca e Formazione in Oftalmologia. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Istituto Internazionale di Ricerca e Formazione in Oftalmologia · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to assess the outcomes between deep anterior lamellar keratoplasty using dehydrated versus standard organ culture stored donor corneas.

Read the detailed description

Keratoconus is a common corneal disease characterized by progressive thinning and steepening resulting in significant visual impairment. With improved instrumentation and corneal imaging technology, deep anterior keratoplasty has been recognized as the preferred primary operative technique for cases of keratoconus requiring corneal transplantation.

Since corneas preserved through organ culture remain viable only for up to 4 weeks, techniques that can extend storage of corneas have been explored.

The objective of this study is to assess the outcomes between deep anterior lamellar keratoplasty using dehydrated versus standard organ culture stored donor corneas.

02

Conditions studied

  • Keratoconus

Browse trials for

03

In context

Keratoconus

307 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's planned enrollment of 60 is above the median of 40 across 203 interventional studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

This is the only study on the registry with Istituto Internazionale di Ricerca e Formazione in Oftalmologia as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Keratoconus
  • Surgical candidates for deep anterior lamellar keratoplasty

Exclusion criteria

Exclusion Criteria:

  • Ocular comorbidities other than cataract (ie. visual significant optic nerve or macular disease)
  • Previous corneal transplantations or other ocular surgeries except uncomplicated cataract surgery
  • Inability to comply with study protocol or participate in follow-up visits
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    DALK using Dehydrated Corneas

    Corneal transplantation of anterior lamellar grafts from dehydrated corneas.

    Procedure: Deep anterior lamellar keratoplasty

  • Active comparator
    DALK using Standard Organ Culture Stored Corneas

    Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.

    Procedure: Deep anterior lamellar keratoplasty

Interventions

  • ProcedureDeep anterior lamellar keratoplasty

    Deep anterior lamellar keratoplasty using dehydrated corneas

  • ProcedureDeep anterior lamellar keratoplasty

    Deep anterior lamellar keratoplasty using standard organ culture stored corneas

06

What researchers measure

Primary outcomes

  1. Change in best spectacle-corrected visual acuity

    Measured as the difference in best spectacle-corrected visual acuity preoperative, 6 and 12 months postoperatively using ETDRS chart

    Time frame: Preoperatively; and 6 and 12 months postoperatively

Secondary outcomes

  1. Change in astigmatism

    Topographic astigmatism (Diopters) is measured using anterior segment optical coherence tomography (CASIA)

    Time frame: Preoperatively; and 6 and 12 months postoperatively

  2. Change in Thinnest-point pachymetry

    Thinnest-point pachymetry values (um) are measured using anterior segment optical coherence tomography (CASIA)

    Time frame: Preoperatively; and 6 and 12 months postoperatively

  3. Change in endothelial cell density

    Measured using noncontact specular microscopy

    Time frame: Preoperatively; and 6 and 12 months postoperatively

  4. Incidence of graft rejection

    Clinically assessed during postoperative examinations

    Time frame: 6 and 12 months postoperatively

  5. Incidence of graft failure

    Clinically assessed during postoperative examinations

    Time frame: 6 and 12 months postoperatively

  6. Corneal donor loss due to preparation

    Based on intraoperative assessment of corneas unusable for corneal transplantation

    Time frame: Intraoperative

Other outcomes

  1. Refraction

    Measured by manifest refraction

    Time frame: 6 and 12 months postoperatively

  2. Adverse Events/Complication

    Comparison of total rates of adverse events/complications assessed clinically

    Time frame: up to 12 months postoperatively

07

Study locations

1 of 1 sites recruiting
  • Ospedali Privati Forlì "Villa Igea"
    Forlì, Emilia-Romagna 47122, Italy
    • Massimo Busin, MD · Contact · mbusin@yahoo.com
    • Massimo Busin, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04430244
Lead sponsor
Istituto Internazionale di Ricerca e Formazione in Oftalmologia
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jun 17, 2020
Primary completion
May 2023 (estimated)
Completion
May 2023 (estimated)
Last update
Jul 7, 2020

Study contacts

Massimo Busin, MD
Contact
mbusin@yahoo.com
+393473448343
Angeli Christy Yu, MD
Contact
angeliyu@gmail.com
+393663903896
Massimo Busin, MD
principal investigator · Università degli Studi di Ferrara

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion